INSULET CORP
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
About Insulet
Surgical & Medical Instruments & Apparatus, SIC 3841
Insulet Corporation develops, manufactures, and sells proprietary continuous insulin delivery devices designed for individuals with insulin-dependent diabetes. Its core offering is the Omnipod tubeless platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the legacy Classic Omnipod. In addition to insulin management systems, the company produces drug delivery pods utilized in Amgen's Neulasta Onpro kits to assist chemotherapy patients. Insulet serves individuals with type 1 and type 2 diabetes through commercial distribution partners, independent wholesalers supplying pharmacy networks, healthcare organizations, and direct consumer channels.
The company distributes its Omnipod product line across 25 countries, with Omnipod 5 commercially available in 19 of those markets. Product manufacturing takes place at automated company-owned facilities located in Acton, Massachusetts, and Johor, Malaysia, alongside contract manufacturing lines in China and an additional facility under development in Costa Rica. Insulet operates facilities and management from Acton, Massachusetts.
Summary of the business section of Insulet's latest annual report, written by StockData.
Company profile
Company
- Legal name
- INSULET CORP
- Headquarters
- Acton, MA
- Address
- 100 Nagog Park 01720
- Phone
- (978) 600-7000
- Employees
- 5,400, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- PODD
- Exchange
- Nasdaq
- IPO date
- May 15, 2007
- Shares outstanding
- 69M, Jul 29, 2026
- Public float
- $22.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1145197
- CUSIP
- 45784P101
- ISIN
- US45784P1012
- LEI
- 549300TZTYD2PYN92D43
- EIN
- 04-3523891
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ashley McEvoy | President and CEO, Director | 23,735 |
| Lisa Blair Davis | SVP, Chief HR Officer | 4,453 |
| Michael Panos | EVP and CCO | 2,782 |
| Eric Benjamin | EVP and COO | 23,600 |
| Lauren Budden | Group VP, CAO and Controller | 8,625 |
| John W. Kapples | SVP and General Counsel | 27,514 |
| Prem Singh | SVP, Global Operations | 6,953 |
| Laetitia Cousin | SVP, Reg, Quality & Compliance | 5,674 |
| Flavia Pease | EVP & CFO | 19,159 |
| Dan Manea | SVP, Chief HR Officer | 9,090 |
| Ana Maria Chadwick | EVP, CFO & Treasurer | 14,263 |
| James Hollingshead | Former President and CEO | 61,247 |
| Mark N. Field | SVP & Chief Technology Officer | 13,411 |
| Robert Luther Huffines | Director | 2,449 |
| Jonathan Jay Mazelsky | Director | 0 |
| Timothy C. Stonesifer | Director | 9,041 |
| Luciana Borio | Director | 4,329 |
| Elizabeth H. Weatherman | Director | 10,352 |
| Timothy J. Scannell | Director | 33,024 |
| Michael R. Minogue | Director | 19,921 |
| Wayne A.I. Frederick | Director | 3,818 |
| Jessica Hopfield | Director | 29,355 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Ashley Mc Evoy | $18.86M | $25.21M | $3.81M | $111 | $99 |
| FY2025 James Hollingshead | $13.22M | -$32.12M | $3.81M | $111 | $99 |
| FY2025 Shacey Petrovic | $0 | $0 | $3.81M | $111 | $99 |
| FY2024 Ashley Mc Evoy | $0 | $0 | $3.34M | $102 | $81 |
| FY2024 James Hollingshead | $13.30M | $32.71M | $3.34M | $102 | $81 |
| FY2024 Shacey Petrovic | $0 | $0 | $3.34M | $102 | $81 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 5,400 full-time employees, representing a 38% increase over the prior year.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 24, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 19, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 17, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 10, 2015 | Late filing | Notification of late filing |
| Jun 7, 2011 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 26, 2010 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 20, 2008 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 15, 2007 | IPO | Initial public offering priced (424B4 prospectus) |
| May 11, 2007 | Listing | Registration of securities on an exchange (Form 8-A) |